Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro.

Brinkman, Herm Jan M; Swieringa, Frauke; Zuurveld, Marleen; Veninga, Alicia; Brouns, Sanne L N; Heemskerk, Johan W M; Meijers, Joost C M

Brinkman, Herm Jan M; Swieringa, Frauke; Zuurveld, Marleen; Veninga, Alicia; Brouns, Sanne L N; Heemskerk, Johan W M; Meijers, Joost C M.

Afiliação

Brinkman HJM; Department of Molecular Hematology Sanquin Research Amsterdam The Netherlands.
Swieringa F; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University Maastricht The Netherlands.
Zuurveld M; Synapse Research Institute Maastricht The Netherlands.
Veninga A; Department of Molecular Hematology Sanquin Research Amsterdam The Netherlands.
Brouns SLN; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University Maastricht The Netherlands.
Heemskerk JWM; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University Maastricht The Netherlands.
Meijers JCM; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University Maastricht The Netherlands.

Res Pract Thromb Haemost ; 6(3): e12699, 2022 Mar.

Article em En | MEDLINE | ID: mdl-35494506

Palavras-chave

anticoagulants; dabigatran; factor V; prothrombin complex concentrate; rivaroxaban

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Res Pract Thromb Haemost Ano de publicação: 2022 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google